Wockhardt has surged 9% to Rs 512 in early morning deals on BSE after the pharmaceutical firm said the UK health regulator has allowed its Kadaiya, Nani Daman facility to manufacture and supply most of the products approved to be produced at the unit.
The company has received communication from the United Kingdom Medicines and Healthcare Products Regulatory Agency whereby they have allowed the company to manufacture and supply most of the products manufactured at the said facility and assessed to be critical to public health, Wockhardt said in a statement.
As a result the net impact on the annualised consolidated revenue is expected to be less than £1 million, out of the total annual consolidated revenue of approximately £18 million, from the said facility, it added.
The stock opened at Rs 482 and touched high of Rs 513 on BSE. A combined around one million shares have changed hands on the counter in early morning deals on BSE and NSE.
The company has received communication from the United Kingdom Medicines and Healthcare Products Regulatory Agency whereby they have allowed the company to manufacture and supply most of the products manufactured at the said facility and assessed to be critical to public health, Wockhardt said in a statement.
As a result the net impact on the annualised consolidated revenue is expected to be less than £1 million, out of the total annual consolidated revenue of approximately £18 million, from the said facility, it added.
The stock opened at Rs 482 and touched high of Rs 513 on BSE. A combined around one million shares have changed hands on the counter in early morning deals on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%